Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. - Wikidata - awgldk - TriplyDB

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.

http://www.wikidata.org/entity/Q37692538

about

Nitric oxide and peroxynitrite in health and disease NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease Clinical Relevance of Biomarkers of Oxidative Stress Pharmacology and Clinical Drug Candidates in Redox Medicine RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5p Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.NOX1, 2, 4, 5: counting out oxidative stress.Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significance Effect of oral organic nitrates on expression and activity of vascular soluble guanylyl cyclase Riociguat for the treatment of pulmonary hypertension.Soluble guanylate cyclase: a potential therapeutic target for heart failure.Novel vasodilators in heart failure.Role of sGC-dependent NO signalling and myocardial infarction risk.Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis.Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia.Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG)Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase.Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells.Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity?Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model.Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.Hypertension alters phosphorylation of VASP in brain endothelial cells.Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.

P2860

Q24645400-D4D2C94B-5EAC-4E79-8F77-4BA87F9D4DEC Q24656131-A470C9D9-E27F-4402-87F1-9BD602DA8327 Q26748869-9165B79F-235D-4AC4-AD83-7ACCBDCCC965 Q26785512-C8C64894-DADB-407A-B044-24D5C47AF023 Q26785525-9AF7EFDE-4096-4F34-A590-7BB51E666611 Q27001569-D9D5C381-B501-4B56-A46B-8EDA0B93E48F Q27024762-6D22FE9A-F0E8-4F73-B339-0D022A4B5FD1 Q28247831-EB0AFA57-CBE9-4938-9F34-AF63EBB79F7E Q28741339-AE502A38-BB5D-4843-B917-F6500BFDFDDF Q30252419-174E59C7-74D1-41CB-81B5-6C6B90741C05 Q30315850-F957B38D-5811-4572-971D-9F822920FAC7 Q33818129-48918D28-BE47-4362-8800-D6B4BA4AFA65 Q35009484-84B9A160-32E9-4063-9F4B-901FA2533028 Q35010064-4952DC42-297D-46AE-9D52-B9149F426090 Q35375986-B73825A5-C6D7-4226-BB0C-FFC8878750F1 Q36529020-B3392935-C1F4-4F43-B412-2DDFE019D8C3 Q36938470-CCAC970D-CCBB-4E25-AED6-AE6045FE0098 Q37851516-E1758F6B-E1C1-4E8D-8CA2-8740E53E9115 Q38012596-DAE5C0CD-C9B3-43C7-BBB1-F0966C7F2438 Q38072635-EE14D12B-A22E-4C37-9E9B-8D6262DFC527 Q38367012-38430B32-F6D3-411B-9567-0B85CAC6604B Q39050535-2284925D-F0F3-4F84-8D64-0A29A80589EC Q39722744-C73FD064-69DB-43B5-9FE8-DCB14DB8AFAF Q39847509-27C4F417-D080-4887-981F-C0A644DD2AAF Q40088433-3C65BD05-2B58-4E8A-87D0-E41484C47A83 Q40423735-B95579CB-D217-4B98-8BD5-A5E71F6168D0 Q41329824-9D9EC9CF-9F60-4B3F-958D-4EB2E9E6A332 Q41767067-69CE5076-DE69-4C1C-B667-F806A41A7A90 Q42030989-6232C4A5-D79C-41E5-AA54-908BDE5A528F Q43159940-C6D829FF-AD7D-48C5-8306-71F0D4931F14 Q46173433-C46C74EA-D42E-4EDC-BCEF-D89FC971D4E1 Q46935958-F871FBE1-980D-4505-9DB5-73EBBADD44E2 Q47159582-451B4102-D121-4B83-AE17-BE2589711DCB Q48358527-BC94C5C1-6D03-49A3-B124-767084E87F46 Q48738058-F9DD571B-F8ED-45FE-AEEB-603F0F0F3EFA Q51682930-DEB58073-B4E7-44F1-BCBE-FE912FFCF937

P2860

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.

http://www.wikidata.org/entity/Q37692538

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@en

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@nl

type

label

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@en

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@nl

prefLabel

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@en

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@nl

P1433

Q37692538-08C3C0D8-D236-43EB-B1CC-399F3C6B1BDF

P1476

Q37692538-62328192-B7BD-4B4D-8F46-6D67065B1964

P2093

Q37692538-083343BD-9E0D-47C1-AA64-C7A5132F7E9B

Q37692538-3EC1BD2C-DCD2-4B32-9909-E2989FA8F021

Q37692538-6814CEA3-F724-4E57-AB5B-C598CC5BBBFD

Q37692538-8B6FB380-E7FC-40F9-BCC5-042B106B32B2

Q37692538-8FA56B13-D08D-4B09-9E13-352C84B20892

Q37692538-9F4464BD-DF9A-4C07-8A21-C24B72E29CA2

Q37692538-C6E8CD5C-C793-4DEC-8F19-0562E7AA8A30

Q37692538-E51AA4E7-31BB-476F-AE6D-CA951D8AEA2D

Q37692538-E9373607-6C54-4536-8E0F-50CB8AAF8524

P2860

Q37692538-086948FB-AA68-4135-8DBC-34059BDC0851

Q37692538-0E21289B-3A66-462C-9956-AFF3FB9A7949

Q37692538-0FE05847-8E80-4014-B1A3-20DCCC387EE0

Q37692538-113C3FD4-1D43-4258-B59E-B4AB287AA759

Q37692538-18D22B84-B35D-45CE-B69C-9096AB2857C6

Q37692538-1AC00EB2-A884-47D6-B135-F1AE709B4C0F

Q37692538-1CEE8B6F-2565-4E4C-98BA-033FC18A510F

Q37692538-1E656D2A-0C18-4331-9B85-E91B497B46D9

Q37692538-212E74CE-C2FD-4082-9B16-4224471DA888

Q37692538-2B2CB0F9-E709-4C93-9CE0-AFFB6699A10B

P304

Q37692538-47E3B9BF-71DA-4D7B-8E0C-4084EFC848F8

P31

Q37692538-C674B10F-5CAC-4657-ADF6-FFFB0C4EE80A

P356

Q37692538-F86B7151-8C45-450C-88CD-5F4D5B2CD98E

P407

Q37692538-EC65DC82-B84D-4624-9A13-F922D638440E

P433

Q37692538-6FC83655-82BF-4824-81E5-BFB225C1F71E

P478

Q37692538-F6204EB4-E35F-41F8-90B1-FB369DA926FB

P577

Q37692538-A64AF1B5-B312-4C53-B90A-38D12A2C446D

P5875

Q37692538-0E060D9A-F8A3-4F01-9DCF-AA42F133736A

P698

Q37692538-61804EBE-CE0B-4598-8B62-3110E362D99E

P921

Q37692538-705F818D-242B-4A88-B7F1-66C1D0A7C5FC

P932

Q37692538-7F887E75-07C1-4380-BE67-56060A00D219

P356

PNAS.0405509101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Reduced cGMP signaling associa ...... in late-stage atherosclerosis.

@en

P2093

Alain Rupin

http://www.w3.org/2001/XMLSchema#string

Arun Kumar H S

http://www.w3.org/2001/XMLSchema#string

Delphine Behr-Roussel

http://www.w3.org/2001/XMLSchema#string

Harald H H W Schmidt

http://www.w3.org/2001/XMLSchema#string

José Rodrigo

http://www.w3.org/2001/XMLSchema#string

L Otto Uttenthal

http://www.w3.org/2001/XMLSchema#string

Tony J Verbeuren

http://www.w3.org/2001/XMLSchema#string

Ulrike Zabel

http://www.w3.org/2001/XMLSchema#string

Volker O Melichar

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme

Human soluble guanylate cyclase: functional expression and revised isoenzyme family

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Atherosclerosis — An Inflammatory Disease

Pterin interactions with distinct reductase activities of NO synthase

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly

Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose

P304

16671-16676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0405509101

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8180116

http://www.w3.org/2001/XMLSchema#string

P698

15546990

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

534521

http://www.w3.org/2001/XMLSchema#string